A recombinant Chinese hamster ovary (CHO) cell clone, S1, stably expressing human insulin-like growth factor binding protein-1 (hIGFBP-1), was treated with polyethylene glycol (PEG), resulting in cell fusion, in order to further enhance the protein expression by increasing the gene copy number and/or the amount of organelles important to the protein expression/-secretion. Both the fused cell line, Peg1, and its mother cell line, S1, were adapted to serum-free growth in suspension and were characterised with respect to growth and productivity. Peg1 was easier to adapt to the serum-free suspension conditions and had a higher viability during the adaptation period than S1. Furthermore, Peg1 showed a stable productivity of hIGFBP-1 that was twice as high as that for S1 under both adherent and suspension conditions. A considerable difference in the specific productivity (up to 3-4 times) was noticed during the growth phase. PEG fusion experiments have earlier been studied in our laboratory with CHO cells producing recombinant factor VIII and our results correlates very well with the results obtained with the factor VIII producing cells. Surprisingly, it was possible to obtain high producing recombinant cell lines, which were stable for more than 4 months.
Introduction
Large scale production of recombinant proteins in mammalian cells requires high expression levels for a successful process. A common approach to obtain high expression is to increase the gene copy number e.g. by gene amplification (dihydrofolate reductase, glutamine synthetase, etc.) (Sharma and Schimke, 1994) . The cell productivity increases at higher gene copy number but it does not increase linearly (Gu et al., 1992; Dyring et al., 1997) . The cells seem to reach a limit at which they cannot make use of any extra gene copies. However, when using the dihydrofolate reductase (DHFR) gene amplification system, increased expression can be achieved in cells cultured over a very long period of time in MTX containing medium. This does not increase the gene copy number. A likely explanation is, however, that the expression and/or secretion rate increases (Dyring et al., 1997) .
Fusion of two different cell lines is a well-known method to achieve a new cell line with characteristics from both parent cells. Somatic cell fusion is also used to enhance specific properties of one of the parent cells. The most common use is in the establishment of hybridoma cells for the production of monoclonal antibodies. Cell fusion as a method of enhancing protein production has been described by Chenciner et al., 1990 . They produced classical hybrids between a liver cell and a transfected Vero cell. The stable hybrid produced an increased amount of hepatitis B surface antigen. A number of different cell fusion protocols are applicable; the use of polyethylene glycol (PEG), protoplast or Sendai virus has been described by Kennett, 1979, electrofusion by Borrbaeck and Hagen, 1989 , and by Chang et al., 1992 . These authors describe the use of classical fusion of two different cells, as a means of obtaining an increased production of a particular product. Stoicheva and Hui, 1994 , have described the fusion of CHO cells by the use of an exponen-tially decaying electric pulse in the presence of PEG, Dextran or Ficoll. They studied the effect of different concentrations and molecular weights of the agents on cell aggregation. PEG causes cell shrinking and aggregation, and after removal of the PEG, cell fusion takes place (Robinson et al., 1979; Krahling, 1981; Hui et al., 1985) . A direct interaction of PEG with membrane lipids is assumed to cause a decrease of the membrane fluidity (Ohno et al., 1981) . The assembly of cell membranes, stabilised by water, is disturbed by strong interaction with the polymer molecules having a strong hydration power, resulting in membrane fusion (Nakajima and Ikada, 1994) .
Human IGFBP-1 is a 26 kDa IGF binding protein with a total of 234 amino acids (Luthman et al., 1993) . It acts as an acute modulator of the metabolic activities of IGF. To understand the regulation of IGF bioactivity at the cellular level, it is necessary to study the IGFBPs. In this paper we present a study on the self-fusion of cells from a CHO line with cells from the same line leading to an increased production of recombinant hIGFBP-1.
Materials and methods

Origin of the S1 mother cell population
A CHO cell clone, S1, stably producing human IGFBP-1 for more than four months was used for these experiments: DHFR-deficient CHO cells (DG44 N.Y., a generous gift from D.L. Chasin) were co-transfected with an IGFBP-1 expression vector and a dhfr-vector.
For gene amplification, selective medium + 0.1 g TPA l 1 (TPA = phorbol 12-myristate 13-acetate) was added to the cells with stepwise increasing concentrations of MTX up to 100 nm MTX. The tumour promotor, TPA, is shown to enhance the frequency of MTX resistance and DHFR gene amplification (Varshavsky, 1981) . Colonies were picked and the one used in this paper was named S1.
PEG fusion of S1 cells
Cells were seeded in 225 cm 2 tissue culture flasks at a concentration of 0.2 10 6 cells ml 1 in 60 ml growth medium (DMEM/F12 (1:1) + 5% BCS (Hyclone, USA)). The medium was replaced every second day with fresh medium. When the cell culture reached around 90% confluence, the cells were detached from the surface by trypsination and washed twice with PBS in a sterile plastic tube. The fusion protocol developed by Adamson and Spira, 1994 , was followed. Polyethylene glycol (PEG 1500 , Sigma, USA), 1 ml, was added dropwise to the pellet during 1 min. The tube was left for 1 min before it was gently rolled back and forth for 3 min. Slowly, the pellet was resuspended in 60 ml fresh growth medium and seeded in a 225 cm 2 tissue culture flask. The cell population was named Peg1. The following day, the procedure was repeated with Peg1 giving Peg2 and repeated again the next day with Peg2 giving Peg3. As a negative control, 1 ml PEG was added to a sub-confluent cell culture in a 6 ml tissue culture flask and was removed after 3 min. Growth medium (6 ml) was then added to the tissue culture flask.
Morphology, size and growth of the cells
The morphology of the cells in the tissue culture flasks was studied in a phase contrast microscope (Olympus LH50A, Japan) provided with a Polaroid camera (Olympus OM-2, Japan) with Polaroid 667 films (Polaroid, UK). In order to determine the cell size, cells were cultured in tissue culture flasks to around 70% confluence. They were detached from the surface by trypsination, washed twice with PBS and resuspended in PBS to a concentration of 10 4 cells ml 1 . The cell sample of about 10 000 cells was measured on the cell analyser system, CASY 1 (Schärfe System, Germany). The number and viability of the cells in suspension were determined by trypan-blue exclusion. The growth rate was determined as mean [(t 2 -t 1 ) 1 ln(C V ; 2 C V ; 1 1 )], where C V was the concentration of viable cells and t was the time interval between time 2 and time 1.
Adaptation of the cells to serum-free suspension growth
S1 and Peg1 were seeded in 225 cm 2 tissue culture flasks at a concentration of 0.2 10 6 cells ml 1 in 60 ml growth medium. The medium was replaced every second day with fresh medium. When the cell culture reached around 90% confluence, the cells were detached from the surface by trypsination and transferred to 50 ml defined serum-free medium, named XDYC4 medium (Table 1) , with 8 g l 1 casein peptone in 250 ml shake flasks (Corning, UK) at a concentration of around 0.5 10 6 cells ml 1 . The shake flasks were then placed on a rotating table (40 rpm) in an incubator with 5% CO 2 and 95% humidity. Sam- Table 1 . The composition of the defined serum-free medium, XDYC4, used for suspension cultivations of S1 and Peg1. DMEM, Hams F12 and glutamine was from Gibco, Scotland; HSA, FeCitrate and ascorbic acid from Pharmacia, Sweden; synperonic from Serva, Germany; glucose and hepes from Sigma, USA; Insulin from Novo Nordisk, Denmark and aprotinin from Pentapharm, Switzerland
XDYC4 medium
DMEM/Hams F12 (1:1) 0.4% HSA 0.5 g l 1 synperonic a total of 4.5 g 1 1 D-glucose a total of 8 mM L-glutamine 3.6 g l 1 hepes 0.6 mM FeCitrate/0.24 mM Ascorbic acid 10 mg l 1 Insulin 75 000 KIU l 1 Aprotinin ples were taken every day and the cell number was determined. Samples were frozen for later IGFBP-1 analysis. The medium was fully replaced every second day. After four days, the cells began to grow as single cells and the medium was changed to XDYC4 medium with 4 g l 1 casein peptone for eight days and then changed to XDYC4 medium without casein peptone. Later on, the cells were transferred to 250 ml spinner flasks in 50 ml XDYC4 medium and cultured herein.
BIACore analysis
Real-time biospecific interaction analysis (BIA) has been used to quantify the amount of hIGFBP-1 produced by the cells as described in Dyring et al. (1997) . The BIAcore T M system from Pharmacia Biosensor AB was used. IGF-I (100 g ml 1 , Pharmacia, Sweden) was immobilised on Sensor Chip CM5 which was then blocked with 1 M Ethanolamine Hydrochloride. Standards of hIGFBP-1 (Pharmacia, Sweden) and undiluted samples were injected. Mab anti-hIGFBP-1 (100 g ml 1 , 6303 Medix Biochemica, Finland) was injected after each sample and the sensor chip was prepared for a new sample by washing with HCl.
Southern blot analysis
DNA was extracted from exponentially growing cells by using the Qiagen Cell Culture DNA kit (Qiagen, USA). The procedure in the Qiagen genomic DNA handbook was followed. The method described in Dyring et al. (1997) 
Immunoblotting
Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting was used to identify hIGFBP-1. Conditioned medium was mixed with 2 sample buffer (0.125 M Tris-HCl pH 6.8, 0.2% glycerol, 0.005% bromophenol blue, 4% (w/v) SDS, 5% beta-mercaptoethanol) and loaded onto a vertical Novex 12% gel (Novex, San Diego, USA) and electroforesed 100 V in running buffer (3 g l 1 Trisma-base, 14.35 g l 1 glycin and 10% SDS). The protein gel was electrophoretically transferred onto Hybond-ECL nitro-cellulose filter (Amersham, UK) at 135 mA using a semi-dry electroblotter (Ancos, Denmark) and 5.8 g l 1 Trisma-base, 4.3 g l 1 glycin, 0.38 g l 1 SDS and 200 ml l 1 MetOH as transfer buffer. The filter was blocked in PBS-T (PBS + 0.1% Tween-20) + 5% milk powder (Semper, Sweden) and the filter was rinsed by washing several times with PBS-T. The filter was then incubated with Mab anti-hIGFBP-1 (6303) in PBS-T and washed as above. The filter was then incubated with peroxidaseconjugated donkey-anti-mouse (715-035-151, Jackson ImmunoResearch, Pennsylvania, USA) in PBS-T and washed as above. The filter was then incubated with ECL Western blotting detection Reagents 1 and 2 (Amersham, UK) and exposed to ECL film (Amersham, UK).
For PAGE, running buffer (10.8 g l 1 Trisma base, 5.5 g l 1 boric acid and 0.74 g l 1 EDTA), 2x sample buffer (0.4% running buffer, 20% glycerol and 0.1% bromophenol blue), and transfer buffer (3.94 g l 1 Trisma base and 14.4 g 1 l glycin) was used. The gels used was vertical Novex 16% gels.
Results
After treatment with PEG, cells were seeded in a tissue culture flask and immediately, the cells began to fuse as shown on Fig. 1 . The picture is taken 5 min after the PEG treatment of Peg2 cells. A fusion between different number of cells can be seen. The cells rapidly attached to and spread on the surface of the tissue culture flask. The three obtained fusion cell populations, Peg1-3, appeared as heterogenous populations of nonfused and fused cells, and the fused cells seemed to be derived from different numbers of cells. The untreated S1 cells cultured adherently had a morphology characterised by a fibroblast-like appearance typically for CHO-DG44 cells cultured adherently (Fig. 2a) . After the cell fusions, the appearance of the cells changed. Examples are given in Fig. 2b-d . The fused cells were larger than their mother cells, S1, and attached to the surface of the tissue culture flasks, cells with a diameter as big as 200 m could be seen. The plasma membrane was very diffuse and the cells appeared extremely thin except from a more defined area in the middle of the cell. This area contained a large amount of shining spots in different sizes, which were most probably different organelles.
Determination of the cell size showed, that the mean diameter of the cell population increased with each fusion step ( Table 2) increased. Analysis of the gene copy number by southern blotting one month after the PEG treatment of the cells showed that Peg1 had twice as many copies of the hIGFBP-1 gene as S1, while Peg2 and Peg3 had 1.5 and 1 times as many copies of the gene, respectively, as S1 (Fig. 3) . S1 and Peg1 was adapted to serum-free suspension cultivation and Fig. 4 shows the growth of S1 and Peg1 in 50 ml XDYC4 medium in 250 ml spinnerflasks. The results shown are a mean of three experiments performed simultaneously with each cell population. There seemed to be no difference in cell growth between the two cell populations. Both cell populations had a growth rate of 0.34 d 1 and reached a maximum number of living cells of 2.3 10 6 cells ml 1 . The viability of Peg1 was more than 90% during the adaptation to serum-free suspension growth while the viability of S1 was 70-90% most of the adaptation period. Fig. 4 also shows the amount of IGFBP-1 that was produced during 48 h periods consecutively. During the growth phase, more than twice as much IGFBP-1 was produced from Peg1 than from S1 and the amount of IGFBP-1 produced in each 48 h production period was higher throughout the whole experiment. The total amount of hIGFBP-1 which was produced during the 15 days cultivation period was twice as high for Peg1 as for S1 as shown in Fig. 5 . According to immunoblotting, there was no apparent difference in the hIGFBP-1 produced from S1 and Peg1 (results not shown). For quantification, the bands in the autoradiograms were scanned, quantitated by determining the area under each peak an normalised to the S1 plasmid band.
Discussion
The described results show, that self-fusion with PEG of the stable recombinant cell line, S1, lead to a stable cell population, Peg1, with an increased specific hIGFBP-1 production and with cells that had an altered appearance. It was observed, that the Peg1 population contained cells that were larger than the S1 cells three weeks after the PEG-treatment. This indicates, that at least a part of the fused cells had survived and that the average cell size had increased. After months of cultivation, the mean Peg1 cells were still larger than the non-fused S1 cells (data not shown) and were stably producing increased amounts of hIGFBP-1. These results correlate very well with the results obtained by Adamson and Spira, 1994 . They found that, by treating stable, recombinant factor VIII producing CHO cells with PEG 4000 , the mean diameter of the cells as well as the specific productivity increased. The increased size of the cells and the increased specific productivity of recombinant factor VIII were stable for more than five months in cultivation.
Southern blotting showed an increased number of hIGFBP-1 gene copies in Peg1 and Peg2 as a result of the cell fusion. As described by Robinson et al., 1979, and Stoicheva and Hui, 1994 , multinucleate cells are formed after polyethylene-induced cell fusion. These cells which have two or more separate nuclei are called heterocaryons. Eventually, a heterocaryon will proceed to mitosis and produce a hybrid cell in which the separate nuclear envelopes have been disassembled, allowing all the chromosomes to be brought together in a single large nucleus (Alberts et al., 1994) . However, such hybrid cells tend to be unstable and lose chromosomes at random giving rise to a variety of hybrid cell lines, each of which contains different numbers of chromosomes. A selection favoring cells with the most optimal number of chromosomes (if any) may occur with time. Our results indicate that a state where the cells have more than one set of chromosomes may be of advantage for some cells, since the mean gene copy number of Peg1 is twice that of S1 after one month of cultivation. Adamson and Spira (1994) , however, did not find any increase in gene copy number or chromosome number in the PEG treated factor VIII producing cells.
The increased specific productivity of hIGFBP-1 in Peg1 could either be a direct result of the increased hIGFBP-1 gene copy number and/or a result of an increased number of organelles, in particular ER, mitochondria and even Golgi as described by Adamson and Spira, 1994 . They studied the PEG-treated recombinant factor VIII producing cells with Transmission Electron Microscopy (TEM) and detected a larger number of high energetic mitochondria in the PEG cells, which indicated that these cells probably had a larger energy pool than their mother cells. The TEM studies were confirmed by FCM (flow cytometry) analyses of mitochondria in living cells after incubation with Rhodamin 123 and in fixed cells after incubation with antibodies against mitochondrion inner membrane. The PEG cells showed a much stronger fluorescence than the mother cell population. A further support for this theory was energy level measurement performed by Adamson and Spira, 1994, that showed, that the amount of ATP/cell was higher for the PEG cells. An increased requirement for ATP in the larger, fused cells may lead to an increase in metabolic capacity and production of ATP and thereby an increase in protein expression rate.
The self-fusion also lead to cells which were less sensitive to adaptation to serum-free suspension growth, observed by the higher viability during the adaptation period. Based on the results obtained by Stoicheva and Hui, 1994 , it is likely to think, that less than 20% of the S1 cells fused, which means that the fused cells in average produced more than 6 times as much hIGFBP-1 as their mother cells. Sorting out the 20-30% largest cells in the Peg1 population by e.g. FACS could most probably lead to a population of cells with a very high specific production of hIGFBP-1.
Peg2 and -3 cells had less hIGFBP-1 gene copies and a lower specific productivity than Peg1 cells. They were bigger and appeared more abnormal in the microscope than Peg1 cells. A maximum cell size where the cells could survive, may have been reached with the first PEG treatment, so that the fused cells in Peg2 and -3 were too abnormal not to be outgrown by smaller, less abnormal cells. This could explain both why the gene copy number of the Peg3 cell population was close to that of S1 and why the specific productivity was lower in the cultures that had been repeatedly fused.
In order to study whether polyethylene glycol (PEG) itself induced higher specific productivity, PEG was added to the cells in such a way that the cells could not fuse (there was no contact between the cells). No increase in specific productivity was observed.
We further investigated whether the higher concentration of IGFBP-1 found in medium from Peg1 was a direct result of a lower protease activity in this cell population. The decrease in the hIGFBP-1 concentration throughout the week of incubation was small and did not differ between the cell populations.
Taken together, these results show that cell fusion by polyethylene glycol treatment induced a stable change in the expression capability of the hIGFBP-1 producing cells. Furthermore, cells which were easier to adapt to serum-free suspension culture and which were less sensitive to mechanical stress, were obtained.
